Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial.

By W. Sandborn, S. Hanauer, S. Katz, M. Safdi, D. Wolf, R. Baerg, W. Tremaine, Therese Johnson, N. Diehl, A. Zinsmeister. Gastroenterology, 2001

949 citations recorded by the source corpus.

Subfields: Genetics, Hematology, Rheumatology

View Paper: https://www.semanticscholar.org/paper/9e81c464e9f847cc07685f2669cff3a3a7ccf847

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. W. Sandborn
2. S. Hanauer
3. G. Lichtenstein
4. Stefan Schreiber
5. Markus F. Neurath

In Rheumatology

1. W. Sandborn
2. D. Tracey
3. Lars Klareskog
4. J. Salfeld
5. P. Tak
6. E. Sasso
7. Stefan Schreiber

Citations in the corpus

• Management of Crohn's Disease in Adults (2001, background): “In contrast, etanercept, a fusion protein consisting of an IgG1 Fc antibody fragment and two soluble TNF p75 receptors, was not effective in the treatment of CD at doses (25 mg subcutaneously twice weekly) that have been effective for rheumatoid arthritis (”
• Binding and functional comparisons of two types of tumor necrosis factor antagonists. (2002, background): “In addition, results of a controlled clinical trial with CDP571, a humanized, anti-TNF mAb of the IgG4 class (Sandborn et al., 2001a) are also shown.”
• Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. (2008, background): “In chronic inflammatory diseases, such as Crohn's disease or RA, there is evidence that the frequency of apoptosis is subnormal in the inflamed tissues and that defective apoptosis may be a cause of inflammation (Sands, 2004; Tak, 2005).”
• ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update (2022, neutral): “[111-116] Thus, monoclonal antibodies are also preferred in patients with IBD.”
• Targeted Anticytokine Therapy in Patients With Chronic Heart Failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL) (2004, neutral): “Upper respiratory infection 80 (26) 86 (28) 93 (30) Diarrhea 49 (16) 52 (17) 57 (19) Headache 36 (12) 45 (15) 35 (11) Flu syndrome 37 (12) 37 (12) 38 (12) Injection-site reaction† 16 (5) 55 (18) 62 (20) Anemia† 8 (3) 23 (8) 17 (6) Chest pain 37 (12) 42 ( 14 ) 56 (18) Abdominal pain 24 (8) 25 (8) 29 ”